Introduction {#s1}
============

Development of the paired sensory organs of the head relies on critical contributions from cranial placodes. Of the cranial placodes, the developmental complexity of the otic placode is especially remarkable for producing the entire inner ear, with its convoluted epithelial labyrinth and rich cell type diversity. The otic placode initially forms a fluid filled cyst, the otic vesicle, which subsequently undergoes extensive proliferation and morphogenesis to produce a series of interconnected chambers containing sensory epithelia ([@bib89]). Sensory epithelia comprise a salt-and-pepper pattern of sensory hair cells and support cells. Hair cell specification is initiated by expression of the bHLH factor Atonal Homolog 1 (Atoh1) ([@bib7]; [@bib13]; [@bib53]; [@bib70]; [@bib90]). Atoh1 subsequently activates expression of Notch ligands that mediate specification of support cells via lateral inhibition. Hair cells are innervated by neurons of the statoacoustic ganglion (SAG), progenitors of which also originate from the otic vesicle. Specification of SAG neuroblasts is initiated by localized expression of the bHLH factor Neurogenin1 (Ngn1) ([@bib5]; [@bib36]; [@bib44]; [@bib70]). A subset of SAG neuroblasts delaminate from the otic vesicle to form 'transit-amplifying' progenitors that slowly cycle as they migrate to a position between the otic vesicle and hindbrain before completing differentiation and extending processes to hair cells and central targets in the brain ([@bib4]; [@bib33]; [@bib85]).

Development of both neurogenic and sensory domains of the inner ear requires dynamic regulation of Fgf signaling. Fgf-dependent induction of Ngn1 establishes the neurogenic domain during placodal stages, marking one of the earliest molecular asymmetries in the otic placode in chick and mouse embryos ([@bib1]; [@bib4]; [@bib45]; [@bib48]; [@bib66]). Subsequently, as neurogenesis subsides, Fgf also specifies sensory domains of Atoh1 expression ([@bib27]; [@bib61]; [@bib67]). Moreover, in the mammalian cochlea different Fgf ligand-receptor combinations fine-tune the balance of hair cells and support cells ([@bib26]; [@bib29]; [@bib49]; [@bib66]; [@bib69]; [@bib81]). In zebrafish, sensory domains form precociously during the earliest stages of otic induction in response to Fgf from the hindbrain and subjacent mesoderm ([@bib20]; [@bib53]). Ongoing Fgf later specifies the neurogenic domain in an abutting domain of the otic vesicle ([@bib32]; [@bib85]). As otic development proceeds, the overall level of Fgf signaling increases, reflected by increasing expression of numerous genes in the Fgf synexpression group, including transcriptional effectors Etv4 (Pea3) and Etv5b (Erm), and the feedback inhibitor Spry (Sprouty1, 2 and 4). Sensory epithelia gradually expand during development and express Fgf, contributing to the general rise in Fgf signaling. Similarly, mature SAG neurons express Fgf5. As more neurons accumulate, rising levels of Fgf eventually exceed an upper threshold to terminate further specification of neuroblasts and delay differentiation of transit-amplifying SAG progenitors ([@bib85]). Additionally, elevated Fgf inhibits further hair cell specification while maintaining support cells in a quiescent state ([@bib8]; [@bib30]; [@bib37]; [@bib46]). Thus, dynamic changes in Fgf signaling regulate the onset, amount, and pace of neural and sensory development in the inner ear.

There is increasing evidence that dynamic regulation of glycolytic metabolism is critical for proper development of various tissues. For example, populations of proliferating stem cells or progenitors, including human embryonic stem cells, neural stem cells, hematopoietic stem cells, and posterior presomitic mesoderm, modify glycolysis by shunting pyruvate away from mitochondrial respiration in favor of lactate synthesis, despite an abundance of free oxygen ([@bib2]; [@bib11]; [@bib21]; [@bib60]; [@bib76]; [@bib88]; [@bib93]). This is similar to 'aerobic glycolysis' (also known as the 'Warburg Effect') exhibited by metastatic tumors, thought to be an adaptation for accelerating ATP synthesis while simultaneously producing carbon chains needed for rapid biosynthesis ([@bib43]). In addition, aerobic glycolysis and lactate synthesis appears to facilitate cell signaling required for normal development. For example, aerobic glycolysis promotes relevant cell signaling to stimulate differentiation of osteoblasts, myocardial cells, and fast twitch muscle ([@bib16]; [@bib52]; [@bib62]; [@bib84]), as well as maintenance of cone cells in the retina ([@bib3]).

In a screen to identify novel regulators of SAG development in zebrafish, we recovered two independent mutations that disrupt the glycolytic enzyme Phosphoglycerate Kinase 1 (Pgk1). Loss of Pgk1 causes a delay in upregulation of Fgf signaling in the otic vesicle, causing a deficiency in early neural and sensory development. We show that Pgk1 is co-expressed with Fgf ligands in the otic vesicle, as well as in the olfactory epithelium and various clusters of neurons in cranial ganglia and the neural tube. Moreover, Pgk1 acts non-autonomously to promote Fgf signaling at a distance by promoting synthesis and secretion of lactate. Lactate independently activates the MAPK pathway, leading to elevated expression of the effector Etv5b, priming the pathway to render cells more responsive to dynamic changes in Fgf levels.

Results {#s2}
=======

Initial characterization of *sagd1* {#s2-1}
-----------------------------------

To identify novel genes required for SAG development, we conducted an ENU mutagenesis screen for mutations that specifically alter the number or distribution of post-mitotic *isl2b:Gfp+* SAG neurons. A recessive lethal mutation termed *sagd1* (*SAG deficient1*) was recovered based on a deficiency in the anterior/vestibular portion of ganglion, which are the first SAG neurons to form. Quantification of *isl2b:Gfp+* cells in serial sections of *sagd1- / *- mutants revealed a \~ 60% deficiency in anterior SAG neurons (which are essential for vestibular function) at 24 and 30 hpf ([Figure 1A,B](#fig1){ref-type="fig"}). The number of anterior neurons remained lower than normal through at least 48 hpf whereas accumulation of posterior SAG neurons (which includes auditory neurons) appeared normal ([Figure 1B](#fig1){ref-type="fig"}). Staining with anti-Isl1/2 antibody, which labels a more mature subset of SAG neurons, showed a similar trend: There was a 60% deficiency in anterior neurons from the earliest stages of SAG development whereas subsequent formation of posterior neurons was normal ([Figure 1---figure supplement 1A--I](#fig1s1){ref-type="fig"}). Of note, the early deficit of SAG neurons did not result from increased apoptosis ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}), and in fact *sagd1- / *- mutants produced fewer apoptotic cells than normal. *sagd1- / *- mutants show no overt defects in gross morphology, although *sagd1- / *- mutants do show deficits in balance and motor coordination indicative of vestibular dysfunction. Mutants typically die by 10--12 dpf.

![Initial analysis of *sagd1.*\
(**A**) Lateral views of *isl2b:Gfp*+ SAG neurons in live wild-type (wt) embryos and *sagd1* mutants at the indicated times. The anterior/vestibular portion of the SAG (outlined in white) is deficient in *sagd1* mutants, whereas the posterior SAG (outlined in red) appears normal. (**B**) Number (mean and s.d.) of *isl2b:Gfp*+ anterior neurons and posterior neurons in wild-type and *sagd1* embryos at the times indicated. Sample sizes are indicated. Asterisks, here and in subsequent figures, indicate significant differences (p\<0.05) from wild-type controls. (**C--F**) Cross-sections through the anterior/vestibular portion of the otic vesicle (outlined) showing expression of *ngn1* in wild-type embryos and *sagd1* mutants at 24 and 30 hpf. (**G, H**) Mean and standard deviation of *ngn1*+ cells in the floor of the otic vesicle (**G**) and in recently delaminated SAG neuroblasts outside the otic vesicle (**H**), as counted from serial sections. (**I--P**) Cross-sections through the anterior/vestibular and posterior/auditory regions of the otic vesicle showing expression of *neurod* in transit-amplifying SAG neuroblasts at 36 and 48 hpf. (**Q**) Mean and standard deviation of *neurod*+ SAG neuroblasts at 30 and 48 hpf counted from serial sections. Sample sizes are indicated (**B, G, Q**).](elife-56301-fig1){#fig1}

To further characterize the *sagd1- / *- phenotype, we examined earlier stages of SAG development. Specification of SAG neuroblasts is marked by expression of *ngn1* in the floor of the otic vesicle, a process that normally begins at 16 hpf, peaks at 24 hpf, and then gradually declines and ceases by 42 hpf ([@bib85]). We observed that early stages of neuroblast specification were significantly impaired in *sagd1- / *- mutants, with only 30% of the normal number of *ngn1+* neuroblasts inside the otic vesicle at 24 hpf ([Figure 1C,D,G](#fig1){ref-type="fig"}). However, subsequent stages of neural specification gradually improved in *sagd1- / *- mutants, such that the number of *ngn1*+ neuroblasts in the otic vesicle was normal by 30 hpf ([Figure 1E,F,G](#fig1){ref-type="fig"}). In the next stage of SAG development, a subset of SAG neuroblasts delaminates from the otic vesicle and enters a transit-amplifying phase. Recently delaminated neuroblasts continue to express *ngn1* for a short time before shifting to expression of *neurod*, which is then maintained until SAG progenitors mature into post-mitotic neurons. In *sagd1- / *- mutants, the number of *ngn1*+ neuroblasts outside the otic vesicle was reduced by 50--60% at every stage examined ([Figure 1H](#fig1){ref-type="fig"}). Similarly, the number of *neurod*+ transit-amplifying cells was strongly reduced in *sagd1- / *- mutants ([Figure 1I--Q](#fig1){ref-type="fig"}). This deficit was more pronounced at 30 hpf (\~60% decrease) than at 48 hpf (\~20% decrease). Moreover, deficit was restricted to anterior transit-amplifying cells that give rise to anterior neurons, which are the first to form, whereas accumulation of later-forming posterior progenitors was normal ([Figure 1Q](#fig1){ref-type="fig"}). In summary, the neural deficit observed in *sagd1- / *- mutants reflects a deficiency in specification of early neuroblasts that normally form the anterior SAG, which is essential for vestibular function. In addition, the continuing deficit in anterior transit-amplifying cells at later stages likely contributes to a long-term deficit in anterior SAG neurons.

We next examined other aspects of otic development in *sagd1- / *- mutants. Expression of prosensory marker *atoh1a* was reduced in both anterior (utricular) and posterior (saccular) maculae at 24 and 30 hpf ([Figure 2A--B'](#fig2){ref-type="fig"}). In agreement, *sagd1- / *- mutants produced roughly 25% fewer than normal hair cells in the utricle and saccule at 36 and 48 hpf ([Figure 2C--E](#fig2){ref-type="fig"}). Because development of SAG progenitors and sensory epithelia both rely on Fgf signaling, we also examined expression of various Fgf ligands and downstream Fgf-target genes. Expression of *fgf3* and *fgf8a* appeared relatively normal in *sagd1- / *- mutants from 18 to 30 hpf ([Figure 2S--T'](#fig2){ref-type="fig"}, and data not shown). However, expression of downstream Fgf-targets *etv5b*, *pax5* and *sprouty4* were severely deficient in the otic vesicle of *sagd1- / *- mutants at 18 hpf ([Figure 2F--H'](#fig2){ref-type="fig"}). Expression of these genes partially recovered by 21 hpf and was only mildly reduced by 24 hpf ([Figure 2I--N'](#fig2){ref-type="fig"}). Despite these changes, markers of axial identity were largely unaffected at 30 hpf, including the dorsal marker *dlx3b*, the ventrolateral marker *otx1*, the anteromedial marker *pax5* and posteromedial marker *pou3f3b* ([Figure 2O--R'](#fig2){ref-type="fig"}). These data suggest that Fgf signaling is impaired during early stages of otic vesicle development but slowly improves during later stages, which could explain the early deficits in sensory and neural specification. However, recovery of Fgf signaling is apparently incomplete or insufficient since production of new hair cells in *sagd1* mutants continues at a reduced rate through at least 48 hpf.

![Sensory development and early Fgf signaling are impaired in *sagd1* mutants.\
(**A--D", F--T'**) Dorsolateral views of whole mount specimens (anterior to the left) showing expression of the indicated genes in the otic vesicle (outlined) at the indicated times in wild-type embryos and *sagd1* mutants. (**E**) Mean and standard deviation of hair cells in the anterior/utricular and posterior/auditory maculae at 36 and 48 hpf in wild-type embryos (black) and *sagd1* mutants (red). Sample sizes are indicated.](elife-56301-fig2){#fig2}

Identification of the *sagd1* locus: A novel role for Pgk1 {#s2-2}
----------------------------------------------------------

To identify the affected locus in *sagd1- / *- mutants, we used whole genome sequencing and homozygosity mapping approaches ([@bib59]). We identified as our top candidate a novel transcript associated with the gene encoding the glycolytic enzyme Phosphoglycerate Kinase-1 (Pgk1) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

The zebrafish genome harbors only one *pgk1* gene, but the locus produces two distinct transcripts ([Figure 3A](#fig3){ref-type="fig"}). The primary transcript (*pgk1-FL*) encodes full-length Pgk1, which is highly conserved amongst vertebrates (nearly 90% identical between zebrafish and human). However, the second *pgk1* transcript, termed *pgk1-alt*, is unique to zebrafish and arises from an independent transcription start site in the first intron of *pgk1-FL*. The expression and sequence of *pgk1-alt* transcript were confirmed by conducting RT-PCR on mRNA harvested from wild-type embryos at 24 hpf ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). There are two short exons (termed exons 1a and 1b) at the start of *pgk1-alt* that encode a novel peptide with either 17 or 31 amino acids, depending on translation start site (see below). *pgk1-alt* then splices in-frame with exons 2--6, which are identical to *pgk1-FL*, followed by a splice into a novel exon (termed exon 6a) containing an in-frame stop codon ([Figure 3A](#fig3){ref-type="fig"}). Exon 6a then splices into exon 7, after which the sequence is identical to *pgk1-FL*. Thus *pgk1-alt* encodes a truncated protein that includes much of the N-terminal half of Pgk1 but presumably lacks glycolytic enzyme activity as the C-terminal peptide is required for ADP/ATP binding. In *sagd1- / *- mutants, *pgk1-alt* contains two nucleotide substitutions leading to loss of a splice acceptor site as well as the translation start codon in exon 1b ([Figure 3B](#fig3){ref-type="fig"}). Either of these SNPs could potentially disrupt expression of *pgk1-alt* protein. *pgk1-alt* transcript abundance is strongly reduced in *sagd1* mutants ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

![Two independent transcripts associated with the *pgk1* locus.\
(**A**) Exon-intron structure of the primary full-length *pgk1* transcript (*pgk1-FL*) and alternate transcript (*pgk1-alt*) arising from an independent transcription start site containing two novel exons (1a and 1b) that splice in-frame to exon 2, and a third novel exon (6a) containing a stop codon. The nucleotide and peptide sequences of exons 1b and 6a are shown. Relative positions of the lesions in *sagd1* affecting exon 1b are indicated (red asterisks). (**B**) Nucleotide sequence near the 5' end of exon 1b showing the SNPs detected in *sagd1* (red font). (**C**) Nucleotide sequence of *pgk1-FL* showing the sgRNA target site (blue font) and the altered sequence of the *x55* mutant allele (red font), which introduces a premature stop codon. (**D--F'**) Cross sections through the otic vesicle (outlined) showing staining with ribo-probe for the entire *pgk1* locus (covering both *pgk1-FL* and *pgk1-alt*) in wild-type embryos. Note elevated expression in the SAG, utricular macula (um), and saccular macula (sm). (**G, H, M, N**) Cross sections through the otic vesicle (outlined) in wild-type embryos and *sagd1* mutants stained with ribo-probe for exon 1 (*pgk1-FL* alone) (**G, H**) or exon 1b (*pgk1-alt* alone) (**M, N**). Accumulation of both transcripts is dramatically reduced in *sagd1* mutants. (**I--L, O--R**) Cross sections through the hindbrain (dorsal up) showing expression of *pgk1-FL* (black) plus *neurod* (red) (**I--L**) or *pgk1-alt* alone (**O--R**). Arrows indicate positions of the trigeminal and facial ganglia. Scale bar, 100 µm.](elife-56301-fig3){#fig3}

To determine which SNP in *sagd1* is most relevant, we tested morpholinos (MOs) designed to mimic either mutation. Injecting wild-type embryos with a splice-blocker to target the exon 1b splice acceptor site (sbMO, [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}) impaired accumulation of *pgk1-alt* transcript ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}) and reduced accumulation of Isl1+ SAG neurons by nearly 40% ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). To design translation blockers (tbMOs), we considered that exon1b contains two in-frame AUG codons that could potentially serve as translation start sites, although the first site (disrupted in *sagd1*) lacks a Kozak consensus. We therefore designed tbMO1 and tbMO2 to target each start site ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). It has been established that MOs can effectively block translation by binding mRNA near the start site and up to 80 nucleotides upstream, whereas binding \>10 nucleotides downstream is ineffective ([gene-tools.com](https://www.gene-tools.com/)). Therefore, tbMO1 is expected block translation from either start site whereas tbMO2 is predicted to block only the second start site. Injecting either translation blocker alone, or in combination, reduced accumulation of Isl1+ SAG neurons by 20--30% ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). The phenotype produced by tbMO2 suggests that the second ATG is more likely to serve as the translation start site, in which case altering the first AUG should not disrupt *pgk1-alt* function. Thus, the first SNP in *sagd1* that disrupts the exon 1b splice acceptor is the likely cause of the mutant phenotype. Interestingly, the translation blockers also impaired accumulation of *pgk1-alt* transcript ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}), suggesting that Pgk1-alt protein is required for normal transcript accumulation.

Although *sagd1* does not alter the sequence of *pgk1-FL*, we examined whether the *sagd1* mutation alters accumulation of *pgk1-FL* transcript. In wild-type embryos *pgk1-FL* transcript (but not *pgk1-alt*) is maternally deposited and is widely expressed at a low level during subsequent stages of development ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}). By 14 hpf *pgk1-FL* upregulates in developing somites ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}), and beginning around 18--20 hpf *pgk1-FL* transcript abundance becomes elevated in clusters of cells scattered throughout the central and peripheral nervous systems ([Figure 3---figure supplement 4C--E](#fig3s4){ref-type="fig"}). Examples of cells with elevated *pgk1-FL* expression include utricular and saccular hair cells, mature SAG neurons, trigeminal and epibranchial ganglia, the midbrain-hindbrain border, reticulospinal neurons in the hindbrain, and the olfactory epithelium ([Figure 3D--G,I,K](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4D--G](#fig3s4){ref-type="fig"}). A similar pattern is observed for accumulation of *pgk1-alt* transcript ([Figure 3M,O,Q](#fig3){ref-type="fig"}). Local upregulation of *pgk1-FL* and *pgk1-alt* is severely attenuated in the nervous system in *sagd1- / *- mutants ([Figure 3D--R](#fig3){ref-type="fig"}), whereas expression remains elevated in somites (data not shown).

To test whether Pgk1-alt function is sufficient to upregulate *pgk1-FL*, we examined the effects of transient misexpression using a heat shock-inducible transgene, *hs:pgk1-alt*. When *hs:pgk1-alt* was activated at 20 hpf, accumulation of *pgk1-FL* was markedly elevated at 23--24 hpf ([Figure 3---figure supplement 5I--N](#fig3s5){ref-type="fig"}). This was in contrast to accumulation of transgenic *pgk1-alt* transcript, which peaked near the end of the heat shock period at 21 hpf but then decayed to background levels by 24 hpf ([Figure 3---figure supplement 5A--H](#fig3s5){ref-type="fig"}). We infer that perdurance of Pgk1-alt protein is sufficient to upregulate *pgk1-FL*. Based on previous studies of yeast and mammalian Pgk1 ([@bib6]; [@bib28]; [@bib42]; [@bib75]; [@bib80]; [@bib79]), it is possible that Pgk1-alt acts to stabilize *pgk1-FL* transcript (See Discussion).

To directly test the requirement for full length Pgk1, we targeted the first exon of *pgk1-FL* using CRISPR-Cas9 and recovered an indel mutation leading to a frameshift followed by a premature stop ([Figure 3C](#fig3){ref-type="fig"}). This presumptive null mutation is predicted to eliminate all but the first 19 amino acids of Pgk1. Expression of *pgk1* is severely reduced in *pgk1- / *- mutants, presumably reflecting nonsense-mediated decay ([Figure 3---figure supplement 4H](#fig3s4){ref-type="fig"}). The phenotype of *pgk1- / *- mutants is nearly identical to *sagd1-/-*: Despite apparently normal early expression of *fgf3* and *fgf8a*, *pgk1- / *- mutants show impaired responses to early Fgf signaling, including reduced otic expression of *pax5* and *etv5b* at 18 hpf, reduced *ngn1* at 24 hpf, a deficiency in *neurod*+ transit-amplifying cells at 24 hpf, and a deficiency in mature *isl2b-gfp*+ SAG neurons at 30 hpf ([Figure 4A--H,Q](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The deficiency of Isl1+ SAG neurons persisted through at least 5 dpf ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Unlike *sagd1* mutants, however, *pgk1- / *- mutants showed a deficiency in both anterior and posterior SAG neurons (reduced 31% and 18%, respectively, at 5 dpf, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). *pgk1- / *- mutants also showed a 20--25% decrease in the number of utricular and saccular hair cells at 36 hpf, 48 hpf and five dpf ([Figure 4T](#fig4){ref-type="fig"}). Other aspects of otic vesicle patterning appeared normal based on expression of regional markers *otx1*, *pou3f3b*, *hmx3a* and *dlx3b* at 24 hpf ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Beyond the inner ear, development of a number of other Fgf-dependent neural cell types are also deficient in *pgk1- / *- mutants, including trigeminal, facial and glossopharyngeal ganglia, reticulospinal neurons in the hindbrain, and the olfactory epithelium ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Although *pgk1- / *- mutants show overtly normal gross morphology, they eventually die around 10--12 days post-fertilization. When *pgk1+ / *- heterozygotes were crossed with *sagd1+ / *- heterozygotes, all intercross embryos developed normally ([Figure 4Q](#fig4){ref-type="fig"}), confirming that *pgk1-alt* and *pgk1-FL* encode distinct complementary functions. We also generated a heat-shock inducible transgene to overexpress *pgk1-FL* (*hs:pgk1*). Activation of *hs:pgk1* at 18 hpf rescued the SAG deficiency in *sagd1- / *- mutants ([Figure 4Q](#fig4){ref-type="fig"}). In contrast, activation of *hs:pgk1-alt* at 18 hpf was not able to rescue *pgk1- / *- mutants ([Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}), whereas activation of *hs:pgk1-alt* at 18 hpf did rescue morphants injected with *pgk1-alt*-sbMO ([Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}). Together, these data show that *pgk1-alt* is required upstream to locally upregulate *pgk1-FL*, which in turn is required for proper Fgf signaling and development of sensory hair cells, SAG neurons and various other Fgf-dependent neurons in the head.

![Initial characterization of *pgk1- / *- mutants and genetic mosaics.\
(**A--F**) Cross sections through the anterior/vestibular region of the otic vesicle (outlined) showing expression of the indicated genes in wild-type embryos and *pgk1- / *- mutants at the indicated times. (**G--J**) Lateral views showing *isl2b-Gfp* expression in live embryos at 30 hpf (**G, H**) and *fgf3* at 24 hpf (**I, J**). The otic vesicle is outlined. (**K--P**) Cross sections through the otic vesicle (outlined) showing positions of lineage labeled wild-type cells (red dye) transplanted into a wild-type host (**K, M, O**) or a *pgk1- / *- mutant host (**L, N, P**). Sections are co-stained with DAPI (**M, N**) and *etv5b* probe (**O, P**). Note the absence of *etv5b* expression in wild-type cells transplanted into the mutant host (**P**). (**Q**) Number of mature Isl1+ SAG neurons at 30 hpf in embryos with the indicated genotypes, except for *sagd1* x *pgk1* intercross expected to contain roughly 25% each of +/+, *sagd1/+*, *pgk1/+* and *sagd1/pgk1* embryos. (**R**) Percent of wild-type donor cells located in the ventral half of the otic vesicle expressing *etv5b* in wild-type or *pgk1- / *- hosts. A total of 151 wild-type donor cells were counted in eight otic vesicles of wild-type host embryos, and 247 wild-type donor cells were counted in eight otic vesicles of *pgk1- / *- host embryos. (**S**) Number of Isl1+ SAG neurons (total, anterior and posterior) in wild-type and *pgk1- / *- mutant embryos at 36 hpf (n = 12), 48 hpf (n = 12) and 120 hpf (n = 4). (**T**) Number of phalloidin-stained hair cells (anterior/utricular and posterior/saccular) in wild-type and *pgk1- / *- mutant embryos at 36 hpf (n = 16), 48 hpf (n = 16) and 120 hpf (n = 10). Sample sizes are indicated (**S, T**).](elife-56301-fig4){#fig4}

Pgk1 acts non-autonomously to promote fgf signaling {#s2-3}
---------------------------------------------------

We note that sites of upregulation of *pgk1-FL* and *pgk1-alt* occurs within or near sites of expression of various Fgf ligands, including sensory epithelia, mature SAG neurons, and other tissues depicted in [Figure 3---figure supplement 4F--G](#fig3s4){ref-type="fig"} ([@bib72]; [@bib83]; [@bib53]; [@bib18]; [@bib82]; [@bib85]). Since expression of *fgf3* and *fgf8a* does not depend on *pgk1* ([Figure 2S-T](#fig2){ref-type="fig"}, [Figure 4I-J](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we asked whether upregulation of *pgk1* depends on Fgf. We found that local upregulation of *pgk1* occurred normally in embryos treated with the Fgf pathway-inhibitor SU5402 ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Thus, *pgk1* and *fgf* genes are not required for each other's expression but could share a common upstream regulator.

To better understand how Pgk1 promotes Fgf signaling during otic development, we generated genetic mosaics by transplanting wild-type donor cells into *pgk1- / *- mutant host embryos. We reasoned that if Pgk1 acts cell-autonomously, as expected for a glycolytic enzyme, then isolated wild-type cells should be able to respond to local Fgf sources within a *pgk1- / *- mutant host. Surprisingly, the majority of the wild-type cells located near the utricular Fgf source in the floor of the otic vesicle in *pkg1- / *- hosts did not express the Fgf-target *etv5b* ([Figure 4J,L,N,P,R](#fig4){ref-type="fig"}). In control experiments, wild-type cells transplanted into wild-type hosts showed normal expression of *etv5b* ([Figure 4I,K,M,O,R](#fig4){ref-type="fig"}). Thus, Pgk1 is required non-autonomously to promote Fgf signaling at a distance.

Pgk1 does not act extracellularly through plasmin turnover {#s2-4}
----------------------------------------------------------

We considered two distinct mechanisms for non-autonomous functions of Pgk1 that have been documented in metastatic tumors. First, tumor cells secrete Pgk1 to promote early stages of metastasis through modulation of extracellular matrix (ECM) and cell signaling ([@bib14]; [@bib31]; [@bib86]; [@bib87]). The only specific molecular function identified for secreted Pgk1 is to serve as a disulfide reductase leading to proteolytic cleavage of Plasmin ([@bib39]), a serine protease that cleaves Fgf as well as ECM proteins required for Fgf signaling ([@bib9]; [@bib19]; [@bib51]; [@bib78]). This raised the possibility that loss of Pgk1 could elevate Plasmin activity and thereby impair Fgf signaling. To test this, we injected translation-blocking morpholino (*plg-*tbMO) to block synthesis of Plasminogen (Plg), the zymogen precursor of Plasmin. Injection of plg-tbMO did not rescue or ameliorate the neural deficiency in *sagd1- / *- or *pgk1- / *- mutants ([Figure 4---figure supplement 6A](#fig4s6){ref-type="fig"}). We also tested a splice-blocker (*plg*-sbMO) to validate MO efficacy. Injection of *plg*-sbMO effectively attenuated *plg* transcript ([Figure 4---figure supplement 6C](#fig4s6){ref-type="fig"}) but did not rescue *pgk1- / *- mutants ([Figure 4---figure supplement 6B](#fig4s6){ref-type="fig"}). Therefore the effects of *pgk1- / *- and *sagd1- / *- do not depend on accumulation of Plasmin.

Aerobic glycolysis is required for otic development {#s2-5}
---------------------------------------------------

The second Pgk1-dependent mechanism employed by metastatic tumors is to upregulate and redirect glycolysis to promote lactate synthesis despite abundant oxygen. This process is often called 'aerobic glycolysis', or the 'Warburg Effect', and is thought to accelerate synthesis of ATP and provide 3-carbon polymers used for rapid biosynthesis ([@bib43]). In addition, lactate secretion facilitates cell signaling in cancer cells ([@bib77]) as well as during certain normal physiological contexts ([@bib41]; [@bib63]; [@bib92]; [@bib95]; Reviewed by [@bib65]). We therefore tested whether blocking glycolysis and/or lactate synthesis in wild-type embryos could mimic the phenotype of *pgk1- / *- and *sagd1- / *- mutants. Treating wild-type embryos with 2-deoxy-glucose (2DG) ([@bib57]) or 3PO ([@bib15]) to block early steps in glycolysis ([Figure 5A](#fig5){ref-type="fig"}) reduced the number of mature SAG neurons to a level similar to that of *pgk1- / *- or *sagd1- / *- mutants ([Figure 5B](#fig5){ref-type="fig"}). Similar results were obtained when these inhibitors were added at 0 hpf or 14 hpf.

![Drugs blocking aerobic glycolysis mimic *pgk1- / *- mutants.\
(**A**) Diagram of the glycolytic pathway and changes associated with the Warburg Effect in which pyruvate is shunted from mitochondria in favor of synthesis and secretion of lactate. The indicated inhibitors were used to block discrete steps in the pathway. In the Warburg Shunt, mitochondrial Pyruvate Dehydrogenase Complex (PDC) is inhibited by elevated Pyruvate Dehydrogenase Kinase (PDK), the activity of which is blocked by DCA. (**B, C**) Scatter plots showing the mean (green) and standard deviation (red) of the number of Isl1/2+ SAG neurons at 30 hpf in embryos with the indicated genotypes and/or drug treatments. Lactate-treatments and some controls were buffered with 10 mM MES at pH 6.2. (**D**) Scatter plats showing the mean and standard deviation of the total number of hair cells at 36 hpf in embryos treated with the indicated drugs. Asterisks show significant differences (p ≤. 05) from wild-type control embryos.](elife-56301-fig5){#fig5}

We next focused on later steps in the pathway dealing with handling of pyruvate vs. lactate. In cells exhibiting the Warburg Effect, transport of pyruvate into mitochondria is typically blocked by upregulation of Pyruvate Dehydrogenase Kinase (PDK) ([@bib12]), thereby favoring reduction of pyruvate to lactate (see Warburg Shunt, [Figure 5A](#fig5){ref-type="fig"}). Dichloroacetate (DCA) blocks PDK activity ([@bib34]), allowing more pyruvate to be transported into mitochondria and thereby forestalling lactate synthesis. Treating wild-type embryos with DCA at 14 hpf mimicked the deficiency of SAG neurons seen in *pgk1- / *- and *sagd1- / *- mutants ([Figure 5B](#fig5){ref-type="fig"}). To directly block synthesis of lactate from pyruvate, wild-type embryos were treated with Galloflavin, an inhibitor of Lactate Dehydrogenase ([@bib17]; [@bib47]; [Figure 5A](#fig5){ref-type="fig"}). Wild-type embryos treated with Galloflavin at 14 hpf also displayed a deficiency of SAG neurons similar to *pgk1- / *- and *sagd1- / *- mutants ([Figure 5C](#fig5){ref-type="fig"}). Finally, to block transport of lactate across the cell membrane, we treated wild-type embryos with either CHC or UK5099, which block activity of monocarboxylate transporters MTC1, 2 and 4 ([@bib23]; [@bib24]; [Figure 5A](#fig5){ref-type="fig"}). Application of either CHC or UK5099 at 14 hpf also mimicked the SAG deficiency in *pgk1- / *- and *sagd1- / *- mutants ([Figure 5C](#fig5){ref-type="fig"}, and data not shown). Treatment of wild-type embryos with 2DG, Galloflavin or CHC also reduced hair cell production to a level comparable to *sagd1- / *- or *pgk1- / *- mutants ([Figure 5D](#fig5){ref-type="fig"}). To further explore the role of lactate, we added exogenous lactate to embryos beginning at 14 hpf and examined accumulation of SAG neurons at 30 hpf. As shown in [Figure 5C](#fig5){ref-type="fig"}, lactate treatment elevated SAG accumulation above normal in wild-type embryos and fully rescued *pgk1- / *- mutants. Lactate treatment also rescued hair cell production in wild-type embryos treated with 2DG, Galloflavin, or CHC ([Figure 5D](#fig5){ref-type="fig"}). Thus, pharmacological agents that block glycolysis, lactate synthesis or lactate secretion are sufficient to mimic the *pgk1- / *- and *sagd1- / *- phenotype, and exogenous lactate is sufficient to reverse these effects.

We next examined whether the above inhibitors and/or exogenous lactate affect Fgf signaling and SAG specification in the nascent otic vesicle. Treatment of wild-type embryos with Galloflavin or CHC reduced the number of cells expressing *etv5b* and *ngn1* at 18 hpf and 24 hpf, respectively ([Figure 6Ag](#fig6){ref-type="fig"}, Ah, Bg, Bh, E), mimicking the effects of *pgk1-/-* ([Figure 6Ab](#fig6){ref-type="fig"}, Bb, C, D). Treatment with exogenous lactate reversed the effects of Galloflavin and CHC ([Figure 6Ai](#fig6){ref-type="fig"}, Aj, Bj) and rescued *pgk1- / *- mutants ([Figure 6Ac](#fig6){ref-type="fig"}, Bc, C, D). Moreover, treating wild-type embryos with lactate increased the number of cells expressing *etv5*b and *ngn1* ([Figure 6Ae](#fig6){ref-type="fig"}, Be, C, D).

![Exogenous lactate reverses the effects of disrupting aerobic glycolysis.\
(**A, B**) Cross sections through the anterior/vestibular portion of the otic vesicle (outlined) showing expression of *etv5b* at 18 hpf (**A**) and *ngn1* at 24 hpf (**B**) in embryos with the indicated genotype or drug treatment. Arrows in (**A**) highlight expression in the ventromedial otic epithelium. (**C**) Mean and standard deviation of the number of *etv5b+* cells in the ventral half of the otic vesicle counted from serial sections of embryos with the indicated genotype or drug treatment. (**D, E**) Mean and standard deviation of the number of *ngn1+* cells in the floor of the otic vesicle counted from serial sections of embryos with the indicated genotype or drug treatment. Asterisks indicate significant differences (p\<0.05) from wild-type controls, or between groups indicated by brackets.](elife-56301-fig6){#fig6}

We also tested whether a deficiency of ATP contributes to the *pgk1- / *- phenotype. Adding exogenous ATP to *pgk1- / *- mutants at 14 hpf did not ameliorate the deficiency in expression of *etv5b*, *ngn1*, or *pax5* ([Figure 6Ad](#fig6){ref-type="fig"}, Bd, C, D; and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Likewise, adding ATP to wild-type embryos at 14 hpf did not significantly affect expression of these genes ([Figure 6Af](#fig6){ref-type="fig"}, Bf, C, D; and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Finally, adding 25 uM sodium azide to wild-type embryos at 14 hpf to block mitochondrial respiration did not significantly impair expression of *ngn1* at 24 hpf ([Figure 6Bk](#fig6){ref-type="fig"}, E). Thus, lactate is critical for early Fgf signaling and SAG specification, but exogenous ATP does not affect these functions. Moreover, the deficiencies in otic development observed in *pgk1- / *- mutants can be attributed to disruption of lactate synthesis and secretion.

Lactate and fgf act in parallel to regulate early otic development {#s2-6}
------------------------------------------------------------------

Fgf regulates gene expression primarily through the PI3K and MAPK/Erk signal transduction pathways, but it is unknown which is most critical for otic development. Treatment of wild-type embryos with U0126, an inhibitor of the MAPK activator Mek ([@bib25]), reduced the number of *ngn1+* cells at 24 hpf ([Figure 6Bl](#fig6){ref-type="fig"}, E) and mature Isl1+ SAG neurons at 30 hpf ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) to a degree similar to or greater than *pgk1- / *- mutants. In contrast, treatment of wild-type embryos with the PI3K inhibitor LY294002 ([@bib55]) had negligible effects on these genes ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}, and data not shown), showing that most of the effects of Fgf are mediated by MAPK/Erk.

Recent findings show that lactate can activate the MAPK/Erk pathway through Ras-independent activation of Raf kinase ([@bib41]), see Discussion). Consistent with this mechanism, the ability of lactate to stimulate production of SAG neurons was completely blocked by co-treatment with U0126 ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). We next investigated whether lactate treatment can bypass the requirement for Fgf signaling. Transient misexpression of dominant negative Fgf receptor from a heat shock-inducible transgene, *hs:dnfgfr1*, fully suppressed *etv5b* expression within two hours of heat shock ([Figure 6Ak](#fig6){ref-type="fig"}; [Figure 7C](#fig7){ref-type="fig"}) and reduced accumulation of SAG neurons by 25% at 30 hpf ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). Importantly, treatment with exogenous lactate partially restored *etv5b* expression when Fgf signaling was blocked ([Figure 6Al](#fig6){ref-type="fig"}; [Figure 7D](#fig7){ref-type="fig"}), although this was not sufficient to restore development of SAG neurons ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). Because developmental defects in *pgk1- / *- and *sagd1- / *- mutants appear to stem from reduced Fgf signaling, we tested whether elevating Fgf can rescue *pgk1- / *- mutants. Activation of *hs:fgf8* at a moderate level (37°C for 30 min) beginning at 16 hpf increased the level of *pax5* expression in the otic vesicle at 18 hpf and expanded the spatial domain ([Figure 7E,G](#fig7){ref-type="fig"}). Activation of *hs:fgf8* in *pgk1- / *- mutants increased expression of *pax5* relative to *pgk1- / *- alone ([Figure 7F,H](#fig7){ref-type="fig"}), but not to the same degree seen in non-mutant embryos. Thus, elevating either Fgf or lactate alone can partially compensate for loss of the other, but full activation of early otic genes requires both Fgf and lactate to fully activate the MAPK/Erk pathway.

![Fgf and lactate are required together for full activation of early otic genes.\
(**A--D**) Dorsolateral view of the otic vesicle (outlined) showing expression of *etv5b* at 18 hpf in wild-type embryos or *hs:dnfgfr1/+* transgenic embryos with or without exogenous 6.7 mM lactate added at 14 hpf, as indicated. Embryos were heat shocked at 39°C for 30 min beginning at 16 hpf. (**E--H**) Dorsal view (anterior to the top) of the hindbrain and otic region showing expression of the otic domain of *pax5* (black arrows) in embryos with the indicated genotypes. Embryos were heat shocked at 37°C for 30 min beginning at 16 hpf. (**I**) A model for how lactate and Fgf signaling converge on MAPK/Erk to increase the pool of phosphorylated activated Etv4/5, enabling cells to respond more quickly and robustly to dynamic changes in Fgf.](elife-56301-fig7){#fig7}

Discussion {#s3}
==========

Enhanced glycolysis and lactate secretion promote fgf signaling {#s3-1}
---------------------------------------------------------------

Metabolic pathways such as glycolysis have traditionally been viewed as 'house keeping' functions but are increasingly recognized for their specific roles in development. We discovered that mutations in *pgk1* cause specific defects in formation of hair cells and SAG neurons of the inner ear, as well as the olfactory epithelium and various cranial ganglia and reticulospinal neurons of the hindbrain, all of which normally show elevated expression of *pgk1* ([Figure 3](#fig3){ref-type="fig"}) and require Fgf signaling ([@bib38]; [@bib50]; [@bib53]; [@bib56]; [@bib82]; [@bib85]). Treatment of wild-type embryos with specific inhibitors of glycolysis or lactate synthesis or secretion mimicked the effects of *pgk1-/-*, indicating that the affected cell types require 'aerobic glycolysis', similar to the Warburg Effect exhibited by metastatic tumors. Developmental deficiencies seen in *pgk1- / *- mutants reflect weakened response to Fgf but are fully rescued by treatment with exogenous lactate. Lactate has been shown to bind and stabilize the cytosolic protein Ndrg3, which in turn activates Raf ([@bib41]) thereby converging with Fgf signaling to activate MAPK/Erk. In support of this mechanism, the stimulatory effects of lactate are blocked by the Mek-inhibitor U0126. The MAPK/Erk pathway activates transcription of *etv4* and *etv5a/b* genes ([@bib71]; [@bib74]). Etv4/5 proteins are also phosphorylated and activated by MAPK/Erk and mediate many of the downstream effects of Fgf ([@bib10]; [@bib58]; [@bib94]). This dual regulation of Etv4/5 implies a feedback amplification step and offers an explanation for why lactate is required to increase the efficiency of early stages of Fgf signaling ([Figure 7I](#fig7){ref-type="fig"}). Specifically, initial activation of MAPK/Erk by lactate would expand the pool of Etv4/5, priming cells to respond more quickly to dynamic changes in Fgf signaling. Without *pgk1*, the initial response to Fgf is sluggish and causes lasting deficits in SAG neurons and slows accumulation of hair cells. Later, as Fgf-mediated feedback amplification continues, Fgf signaling gradually improves on its own and is sufficient to support normal development of posterior SAG neurons in *sagd1* mutants, although accumulation of SAG neurons and hair cell continues at a slower pace in *pgk1- / *- mutants.

It is interesting that sites of *pgk1* upregulation correlate with sites of Fgf ligand expression. Fgf expression does not require *pgk1* ([Figure 2S--T'](#fig2){ref-type="fig"}), and *pgk1* upregulation does not require Fgf ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}), suggesting co-regulation by shared upstream factor(s). Analysis of genetic mosaics showed that isolated wild-type cells transplanted into *pgk1- / *- host embryos failed to activate *etv5b* despite close proximity to sensory epithelia, a known Fgf-source. Clearly wild type cells retain the ability to perform glycolysis, but since upregulation of *pgk1* in the otic vesicle is limited to sensory epithelia and mature SAG neurons ([Figure 3A--G](#fig3){ref-type="fig"}), other otic cells may be unable to generate sufficient lactate to augment Fgf signaling. This raises the interesting possibility that Fgf and lactate must be co-secreted from signaling sources to support full signaling potential. Indeed, this model explains why SAG neuroblasts in the otic vesicle, which do not detectably express *pgk1* or *fgf* genes, require both to be expressed in nearby tissues for proper specification. Note, we cannot exclude the possibility that lactate acts cell-autonomously to promote secretion of Fgf ligand, but such a mechanism has never been reported and does not explain why blocking lactate transport mimics the effects of *pgk1- / *- and *sagd1* mutations.

Regulation of Pgk1 by Pgk1-alt {#s3-2}
------------------------------

The *sagd1* mutation does not directly affect full length Pgk1, but instead disrupts a novel transcript arising from an independent downstream transcription start site that appears to reflect an ancient transposon insertion. The first 17 amino acids of Pgk1-alt are novel but downstream the sequence is identical to exons 2--6 of Pgk1-FL. Production of Pgk1-alt is necessary and sufficient for upregulation of *pgk1-FL*, possibly involving transcript stabilization. Exon 6 of zebrafish Pgk1-FL and Pgk1-alt corresponds closely to the STE (stabilizing element) of yeast Pgk1 ([@bib75]). Premature stops within the first half of yeast *Pgk1* lead to nonsense-mediated decay (NMD) of the transcript, but later stops (occurring downstream of the STE) do not trigger NMD ([@bib22]). The STE can also stabilize recombinant transcripts containing foreign sequences that include a 3'UTR that normally destabilizes the transcript independent of NMD. In each case the STE must be translated in order to function, raising the possibility that the corresponding peptide is required for stability ([@bib75]). Several recent studies have identified full length Pgk1 in yeast and human as an unconventional mRNA-binding protein ([@bib6]; [@bib42]), and human Pgk1 can bind specific mRNAs to affect stability, though often by destabilization ([@bib28]; [@bib79]). Whether Pgk1 increases or decreases mRNA stability could reflect interactions with specific sequences or secondary structures in the target. In any case, it seems reasonable that the STE of Pgk1-alt has been coopted from an established 'moonlighting' function of Pgk1 to locally upregulate *pgk1-FL* by increasing transcript stability, thereby facilitating the switch to Warburg metabolism.

Despite the requirement for *pgk1-alt* in the developing nervous system, it is not required in mesodermal tissues. For example, upregulation of *pgk1* in developing somites is not affected in *sagd1- / *- mutants. Curiously, *pgk1* is not appreciably upregulated in presomitic mesoderm, despite the fact that somitogenesis involves a gradient of aerobic glycolysis and lactate synthesis that is highest in the tail and declines anteriorly ([@bib11]; [@bib60]; [@bib62]). However, establishment of Warburg-like metabolism does not necessarily require elevated *pgk1*. Conversely, elevated *pgk1* does not necessarily indicate a Warburg-like state. Indeed, upregulation of *pgk1* in somites likely provides high levels of pyruvate to favor robust mitochondrial ATP synthesis over lactate synthesis ([@bib62]). Although we detected no obvious defects in somite formation in *pgk1- / *- or *sadg1- / *- mutants, it is possible that later aspects of somite differentiation, muscle physiology, etc. are affected.

Although the *sagd1* mutation was recovered in a forward ENU mutagenesis screen, we note that the SNPs detected in the *pgk1-alt* sequence were previously reported in the genome sequence database. It is therefore likely that familial breeding during our screen allowed generation and detection of homozygous carriers of this preexisting allele. Indeed, we have subsequently detected these SNPs in our wild-type stock, likely accounting for variation in expression levels in early otic genes sometimes detected in specific families. As a cautionary note, the sequence for *pgk1-alt* was initially represented in older versions of the annotated zebrafish genome but has since been removed, presumably deemed a technical artifact. However, RT-PCR amplification of sequences expressed at 24 hpf confirmed the presence of *pgk1-alt*. Had we used more recent versions of the genome as our reference dataset, the SNPs in *sagd1* would have been overlooked. Regardless of its origins, identification of the *sagd1* mutant allele underscores the continuing utility of forward screens: Had we not recovered *sagd1* from our screen, it is highly unlikely that we would have identified *pgk1* as a developmental regulatory gene.

Materials and methods {#s4}
=====================

Fish strains and developmental conditions {#s4-1}
-----------------------------------------

Wild-type embryos were derived from the AB line (Eugene,OR). For most experiments embryos were maintained at 28.5°C, except where noted. Embryos were staged according to standard protocols ([@bib35]). PTU (1-phenyl 2-thiourea), 0.3 mg/ml (Sigma P7629) was included in the fish water to inhibit pigment formation. The following transgenic lines were used in this study: Tg*(hsp70:fgf8a)^x17^* ([@bib54])*, Tg(Brn3c:GAP43-GFP)^s356t^* ([@bib91]), Tg*(−17.6isl2b:GFP)^zc7^* ([@bib68]), Tg*(hsp70I:dnfgfr1-EGFP)^pd1^* ([@bib40]), and new lines generated for this study Tg*(hsp70I:pgk1-FL)^x65^* and Tg*(hsp70I:pgk1-alt)^x66^*. These transgenic lines are herein referred to as *hs:fgf8, brn3c:GFP*, *Isl2b:GFP*, *hs:pgk1-FL*, *hs:pgk1-alt*, and *hs:dnfgfr1* respectively. Mutant lines *sagd1^x40^* and *pgk1^x55^* were used for loss of function analysis. Homozygous *sagd1- / *- and *pgk1- / *- mutant embryos were identified by a characteristic decrease in the expression of *Isl2b-Gfp* observed at stages after 24 hpf. At earlier stages, homozygous *pgk1- / *- mutant embryos were identificed by indel-PCR genotyping using the following primers (5'−3') in a single reaction: *pgk1*-fwd-1, AGGTCATTCTCATTCGGGAAC; *pgk1*-indel-1, [AAGGAAAGCGGGTGATCATG]{.ul}; *pgk1*-rev-1, ACGTTAAAGGGCATACGACG. *pgk1*-fwd-1 produces an amplicon of \~250 bp from both wild-type and mutant DNA, whereas *pgk1*-indel-1 produces an amplicon of 127 bp from wild-type DNA only. Adult *pgk1+ / *- heterozygotes were identified using the following primers in a single reaction: *pgk1*-fwd-2, [GCAAGTACATCCAATTGCCG]{.ul}; *pgk1*-indel-2, CGGGTGAGTAAAAGCGGG; *pgk1*-rev-2, [ACGCGTGACAGATACACTTCC]{.ul}. *pgk1*-fwd-2 produces an amplicon of \~451 bp from both wild type and mutant DNA, whereas *pgk1*-indel-2 produces an amplicon of 236 bp from mutant DNA only. *hs:pgk1*-FL and *hs:pgk1*-alt carriers were identified by in situ hybridization using probes for *pgk1*-FL and *pgk1*-alt transcripts following heat-shock at 39°C for 1 hr, or by PCR genotyping using DNA extracted from tails of single embryos, and the following primers (5'−3'): hsp-Fwd, GACGAGGTGTTTATTCGCTCT; reverse primer, ACTGCAGCCTTGATTCTCTG, yielding an amplicon of \~700 bp.

Gene misexpression and morpholino injections {#s4-2}
--------------------------------------------

Heat-shock regimens were carried in a water bath at indicated temperatures and durations. Embryos were kept in a 33°C incubator after the heat-shock. Knockdown of *pgk1-alt* was performed by injecting wild-type embryos at the one-cell stage with \~5 ng of translation-blocking morpholino oligomer tbMO1 (5'-AGCATGAGTTTCTTCCAAGTGCACC-3') or tbMO2 (5'-GTCAGTTGGCATTTCTGTGTGGACT-3'), or 10 ng of splice-blocker sbMO (5'-TCCCCACAGACTAAAGACAATCAGT-3'). Knockdown of *plasminogen* was performed by injecting one-cell embryos with \~5 ng of translation-blocker *plg*-tbMO (5'-AACTGCTTTGTGTACCTCCATGTCG-3') or splice-blocker *plg*-sbMO (5'-AGCATCCTTACCTGTAAAAAGAAAG-3'). Although none of these knockdown conditions, by themselves, caused visible morphological changes or cell death, as a precaution all morpholinos were co-injected with \~5 ng *p53*-MO to suppress non-specific cell death.

RNA extraction and RT-PCR {#s4-3}
-------------------------

For *plg* RT-PCR, RNA was extracted from groups of 50 embryos at 30 hpf using Trizol (Life Technologies) and chloroform (MACRON fine chemicals). For *pgk1*-FL and *pgk1*-alt RT-PCR, RNA was extracted from groups of 50 wild type embryos at 2--4 cell stage or 24 hpf using Trizol and chloroform or a total RNA miniprep kit (NEB), including an on-column DNase I treatment. Trizol and chloroform extracted samples were treated with RQ1 DNase (Promega), and re-purified using a RNA cleanup kit (zymo). Reverse transcriptions were performed in 20 μl reactions containing 0.9--1.5 μg of purified RNA, using SuperScript IV and SuperScript First-strand synthesis kit (Invitrogen). 1--3 μl of reverse transcription products were used as templates in PCR reactions, except for *actin* RT-PCR which 1:10 diluted reverse transcription products were used. RT-PCR were performed with Taq DNA polymerase (NEB) at extension temperature of 68°C. Gene/transcript specific primer pairs (5'−3') and annealing temperatures are as follows: *plg* CGACATGGAGGTACACAAAG (Forward) and GAAGGACCTGCATGTAAAGG (Reverse), 49°C; *pgk1*-FL AGGTCATTCTCATTCGGGAAC (F) and ACTGCAGCCTTGATTCTCTG (R), 51°C; *pgk1*-alt AACTCATGCTAACACGGGGA (F) and ACTGCAGCCTTGATTCTCTG (R), 52.9°C; *actin* AGGTCATCACCATCGGCAAT (F) and CAATGAAGGAAGGCTGGAACAG (R), 49 or 49.7°C.

In situ hybridization and immunohistochemistry {#s4-4}
----------------------------------------------

Whole mount in situ hybridization and immunohistochemistry protocols used in this study were previously described ([@bib64]). Whole mount stained embryos were cut into 10 µm sections using a cryostat as previously described ([@bib85]). The following antibodies were used in this study: Anti-Islet1/2 (Developmental Studies Hybridoma Bank 39.4D5, 1:100), Anti-GFP (Invitrogen A11122, 1:250), Alexa 546 goat anti-mouse or anti-rabbit IgG (ThermoFisher Scientific A-11003/A-11010, 1:50). Promega terminal deoxynucleotidyl transferase (M1871) was used according to manufacturer's protocol to perform the TUNEL assay.

Cell transplantation {#s4-5}
--------------------

Wild-type donor embryos were injected with a lineage tracer (tetramethylrhodamine labeled, 10,000 MW, lysine-fixable dextran in 0.2 M KCl) at one-cell stage and transplanted into non-labeled wild-type or *pgk1* mutant embryos at the blastula stage. A total of 151 and 247 transplanted wild type cells were visualized in the ears of wild-type embryos and *pgk1* mutants, respectively, (n = 8 otic vesicles each) and analyzed for the expression of *etv5b.*

Pharmacological treatments {#s4-6}
--------------------------

The pharmacological inhibitors used in this study include Hexokinase inhibitor 2DG (2-Deoxy-Glucose, Sigma D8375), PFKFB3 inhibitor 3PO (Sigma SML1343), Pyruvate Dehydrogenase Kinase inhibitor DCA (dichloroacetate, Sigma 347795), Lactate Dehydrogenase inhibitor Galloflavin (Sigma SML0776), MCT1/2/4 inhibitors CHC (á-cyano-4-hydroxycinnamic acid, Sigma C2020) and UK-5099 (Sigma PZ0160), MEK inhibitor U1026 (Sigma U120) and PI3K inhibitor LY294002 (Sigma L9908). All inhibitors were dissolved in a 10 mm DMSO stock solution and diluted into the final indicated concentrations in fish water. Lactate treatments were performed with a 60% stock sodium DL-lactate solution (Sigma L1375) diluted 1 to 1000 in fish water to a final concentration of 6.7 mM, and buffered with 10 mm MES at pH 6.2. Note, lactate treatment has little effect on embryonic development at higher pH (not shown). Treatments were carried in a 24-well plate with a maximum of 15 embryos per well in a volume of 500 µl each.

Statistics and quantitation {#s4-7}
---------------------------

Student's t-test was used for pairwise comparisons. Analysis of 3 or more samples was performed by one-way ANOVA and Tukey post-hoc HSD test. Sufficiency of sample sizes was based on estimates of confidence limits. Sample sizes are indicated in Figures or legends. Hair cells were counted in whole mount specimens expressing *brn3c:GFP*, or by phalloidin-staining. Mature SAG neurons were counted by staining embryos with anti-Isl1/2 antibody and counting stained nuclei in whole mount preparations, or by counting *isl2b:GFP*+ SAG neurons in serial sections (2--4 embryos each) counter-stained with DAPI. For quantitation of gene expression patterns detected by in situ hybridization, stained cells were counted in serial sections (2--6 embryos each) counter-stained with DAPI. In some cases, as indicated in the text, whole mount gene expression domains were quantified from by measuring cross-sectional areas using Photoshop. Otherwise characteristic changes in whole mount gene expression reported herein were fully penetrant amongst mutant embryos but were not observed in wild-type embryos.

Whole genome sequencing and mapping analysis {#s4-8}
--------------------------------------------

Adult zebrafish males derived from the AB line were mutagenized using the alkylating agent N-ethyl-N-nitrosourea (ENU) and outcrossed to *Isl2b: GFP* + females as previously described ([@bib73]). *sagd1* mutants were identified in the screening process due to the decreased expression of *Isl2b:Gfp* in vestibular SAG neurons. For the mapping analysis, *sagd1* mutants were outcrossed to the highly polymorphic zebrafish WIK line. A genomic pool of 50 homozygous mutants were collected from the intercrosses between 3 pairs of heterozygous *sagd1* carriers of the AB/WIK hybrid line and sent for whole genome sequencing at Genomic Sequencing and Analysis Facility (GSAF) at the University of Texas-Austin. Sequence reads were aligned using the BWA alignment software. Bulk segregant linkage and homozygosity mapping of the aligned sequences were performed using Megamapper ([@bib59]). Both approaches identified the *pgk1* locus as the top candidate lesion in *sagd1* mutants.
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Reviewer \#1:

The manuscript by Kantarci et al. deals with the activation of the lactate pathway during inner ear development. The authors uncover, through two different mutants, that loss of lactate synthesis reduces Fgf activity and affects hair cell formation and neurogenesis. The results are novel and interesting by linking for the first time a metabolic route with a classical developmental pathway. The authors by providing a wealth of different experiments and methodologies demonstrate the implication of this pathway in ear development.

1\) The expression of *pkg1* is shown starting at 24hpf, where it is expressed in hair cells and mature SAG neurons. Since the strongest effects on *etv5*, *pax5* are observed at 18hpf and 24 hpf, it is not clear how this is correlated with pkg1 expression starting later than the effects and in restricted domains. It is very important that the early expression of pkg1 in the inner ear is shown since maybe the effects on early Fgf upregulation are not related directly to an ear phenotype but from other indirect effects.

2\) The main rational of the paper for early effects of *sagd1* on Fgf activity and not later as well as an effect on the anterior (earlier development) but not posterior SAG, relies on the idea that *pgk1-alt* is required to upregulate *pgk1FL* and stabilize its mRNA. For this, the upregulation of *pgk1FL* should be shown better and in the inner ear. Moreover, the dynamics of mRNA decay in the mutant is not shown and could be shown by PCR. Mutagenic mutations in the STE of the pgk-alt could demonstrate that this is indeed the mode of action of *pgk1alt*.

3\) On the other hand, the effects on hair cells and neurons is related to the expression of pkg1 in these cells? *Pgk1* does not seem to be expressed in the neurogenic domain but in mature neurons. How does loss of *Pgk1* affect neurogenesis at early time points?

Is *pgk1* expressed only in a subdomain of the SAG that could explain why only \"vestibular\" and not auditory neurons are affected? Please, show the expression of *pgk1* in the entire axis of the SAG.

I think that is misleading to talk about vestibular and auditory SAG, since the portion of the SAG that innervates the posterior macula, also innervates the posterior crista which is vestibular. Therefore, the separation into vestibular and auditory might be confusing in zebrafish and not as straight forward as in mammals because neurons innervating vestibular sensory organs are not segregated into different SAGs.

4\) The authors indicate that other markers not related to Fgf signaling, such as Otx1b, dlx3b are not affected. However, these effects are only shown at 30hpf , when the authors mention that the effects of *pgk1* are minor. At this stage, *pax5* is also recovered, compared to the effect at 18hpf. Thus, to fully demonstrate that other markers in the inner ear are not changed and only Fgf signaling, the authors should show otx1b, dlx3b expression at 18hpf and Fgf ligands at these stages.

5\) How are neurons counted in Figure 1? Are nuclei stained with DAPI to assess individual cells? With only cytoplasmatic staining of the isl2b reporter line, can individual cells be counted? Counting information is missing in MM. Which is exactly the posterior isl2b portion? The anterior SAG is outlined in Figure 1A but not posterior SAG. Are neurons counted though confocal sections? Again, it is not clear how counting is done as Figure 1C with overexposed images nor in Figure 2GN with ISH images of highly packed neurons.

6\) If *pgk1* loss delays the upregulation of Fgf signaling, can the phenotype in anterior SAG or hair cells be recovered at later stages ( i.e 5 dpf?).

7\) The authors discuss that the early effects are due to strong effect on Fgf upregulation early but not later, however, it is also possible that at later stages, other mechanisms compensate the lack of *pgk1alt* at later stages. Could it be that *pgk1alt* has only a maternal effect?

8\) The loss of isl2b neurons in *pgk1* mutants (Figure 5H) is almost entire and affects anterior and posterior portions of the SAG. This phenotype seems stronger than the one of *sagd1* mutant. Is this so?

9\) Can the authors show lactate secretion by using a fluorescent glucose substrate?

10\) Authors state that Fgf ligand expression is not affected, but reduction in *Fgf3* is observable in Figure 5J. Could *pgk1* be upstream to Fgf signaling? On the other hand, does treatment of inner ear with SU5402 affect *pgk1* expression?

Reviewer \#2:

The paper by Kantarci et al. focuses on the phenotype of mutant in which the *pgk1* gene is disrupted in zebrafish. The authors show that the mutant exhibits impaired Fgf-dependent development of hair cells and neurons in the otic vesicle and other neurons in the cranial ganglia and neural tube. The authors conclude that the crucial missing component in these mutant embryos is the loss of secreted lactate that is normally produced as a result of modified glycolysis that shunts pyruvate away from mitochondrial respiration in favor of lactate synthesis. They conclude that this secreted lactate activates the ERK MAPK pathway, which in turn primes the Fgf pathway to respond better to dynamic changes in Fgf.

The work is very interesting as it demonstrates that glycolytic enzymes that are usually thought of as housekeeping enzymes, actually play crucial roles in embryonic development.

In general the study is thorough, but there are several places where key experiments are missing and where more data are required.

1\) Many of the experiments require quantitation. This has been done for some, but I think it should be done for all experiments where the authors want to conclude that gene expression is altered in a quantitative way. This is the case for Figure 3, Figure 4, and Figure 5. It is also crucial for the authors to indicate how many embryos they studied for each condition and how many showed the effects they are presenting. In addition, in Figure 2M and N. These data do not seem to match with the quantitations. Why is this?

2\) Some of the in situs are rather poor quality and it is difficult to see the effect that the authors indicate. This is true of the in situs in Figure 3 and Figure 4S-X.

In Figure 3 it is not at all evident that sprouty 4 is affected by the *sagd1* mutation. Moreover, there is legend missing for Figure 3, and I think also labels missing in the Figure.

In Figure 4, it is not clear what is being shown in Figure 4S-Z. These images need to be much higher quality, and more clearly labeled to be able to draw any conclusions.

3\) The authors conclude that the *sagd1* mutations are a result of disrupting the alternative spliced form of *pgk1* (*pgk1-alt*). This needs to be much more rigorously proven. What is the evidence in vivo that *pgk1-alt*, which has the exons 1a and 1b, also does not have the rest of FL *pgk1* downstream of exon 6? In other words, why do they think that only this transcript (ie exons1a, 1b 2-6) then splices to exon 6a. This needs to be proven. It is important that the authors show exactly what transcripts are normally present in the embryo.

They also should show that the *sagd1* mutations really do lead to no protein as a result of the mutated splice site or loss of the start codon.

Finally, they conclude that somehow the loss of *pgk1-alt* leads to destabilization of *pgk1-FL*. This needs to be demonstrated directly. It is much too speculative at the moment.

4\) The model that the authors propose replies on the concept of lactate secretion. I think that a weakness of the paper is that this is assumed to occur, but not shown. This needs to be demonstrated directly. Also, the authors should demonstrate that this really does lead to upregulation of ERK MAPK, which is a key assumption in the paper.

Reviewer \#3:

Kantarci et al. present an interesting study of changes in Fgf signaling and otic placode development after alterations in glycolysis. They describe the isolation and characterization of mutations affecting expression of *pgk1*. One allele, *sagd1*, affects an alternate transcript, suggesting a mechanism that regulates levels through a post-transcriptional mechanism. The authors present evidence that changes in glycolysis alter Fgf signaling.Together it is an interesting study that would potentially have broad appeal. There are several issues that need to be addressed:

The identification of the molecular nature of the *sagd1* mutant is not completely clear. The authors describe the nucleotide changes as background mutations in their stocks. The causality of these changes would be strengthened by linkage analysis genotyping individual embryos.

It is not clear what the evidence is for the *pgk1-alt* gene model. Has this been characterized by analysis of transcripts?

The authors should report whether the *hs:pgk1-alt* transgene is sufficient to rescue *sagd1* mutants. Following the author\'s logic, the *hs:pgk1-alt* transgene would not rescue *pgk1* mutants; this should also be tested.

Some clarity is needed for the phenotypes of *pgk1* mutants. Are they identical to sagd mutants -- grossly normal, viable until 10-12d? Are there hair cell phenotypes in *pgk1* mutants? Are the trigeminal and reticulospinal phenotypes described for *pgk1* mutants also found in sagd mutants? Is there compensatory *pgk1* mRNA from maternal contributions?

Experiments testing the potential role of changes in plasmin in causing *pgk1* mutant phenotypes were incomplete. There were no positive controls for plasminogen morpholino oligonucleotides showing that plasmin levels were actually affected. There are sensitive commercial assays available to measure plasmin activity. Plasmin levels in wt and mutant animals should be measured, and levels after MO injection should be tested.

The authors hypothesize that Fgf and lactate converge on Mapk signaling. They should test this directly by assessing whether lactate treatment can partially rescue SAG neuron number after Mapk inhibitor treatment.

The authors should comment on whether the interference with lactate metabolism on Fgf signaling is specific, or whether other signaling pathways are also affected.

10.7554/eLife.56301.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> The manuscript by Kantarci et al. deals with the activation of the lactate pathway during inner ear development. The authors uncover, through two different mutants, that loss of lactate synthesis reduces Fgf activity and affects hair cell formation and neurogenesis. The results are novel and interesting by linking for the first time a metabolic route with a classical developmental pathway. The authors by providing a wealth of different experiments and methodologies demonstrate the implication of this pathway in ear development.
>
> 1\) The expression of pkg1 is shown starting at 24hpf, where it is expressed in hair cells and mature SAG neurons. Since the strongest effects on etv5, pax5 are observed at 18hpf and 24 hpf, it is not clear how this is correlated with pkg1 expression starting later than the effects and in restricted domains. It is very important that the early expression of pkg1 in the inner ear is shown since maybe the effects on early Fgf upregulation are not related directly to an ear phenotype but from other indirect effects.

We now show a time course of *pgk1* expression in Figure 3---figure supplement 5. We show that *pgk1* transcript is maternally supplied. Zygotic *pgk1* is broadly expressed at a low level but begins to upregulate in somites at 14 hpf, followed by upregulation in clusters of cells in the CNS and PNS beginning around 18 hpf and reaching maximum intensity by 24 hpf.

> 2\) The main rational of the paper for early effects of sagd1 on Fgf activity and not later as well as an effect on the anterior (earlier development) but not posterior SAG, relies on the idea that pgk1-alt is required to upregulate pgk1FL and stabilize its mRNA. For this, the upregulation of pgk1FL should be shown better and in the inner ear. Moreover, the dynamics of mRNA decay in the mutant is not shown and could be shown by PCR.

Although *pgk1* expression does show regional upregulation, it is nevertheless expressed at a relatively low level (in the ear) that is not terribly clear in whole-mounts. We feel that sections of 24 hpf embryos shown in Figure 4 provide the clearest images for expression in the otic vesicle and SAG neurons. Figure 4 also shows that expression of *pgk1* is severely reduced in *sagd1* mutants at 24 hpf, when regional upregulation of *pgk1* is maximal. Earlier stages are less informative because the degree of upregulation in wild-type is still rather low. We also performed an RT-PCR analysis of *pgk1* transcript abundance in wt and mutants but observed no difference in amplicon intensity despite the clear reduction seen by wholemount in situ hybridization (Figure 3---figure supplement 4G and H). The likely reason for this is that upregulation in the CNS/PNS is highly localized and adds little to the overall basal expression in the rest of the embryo.

> Mutagenic mutations in the STE of the pgk-alt could demonstrate that this is indeed the mode of action of pgk1alt.

Although we speculated in the Discussion that the STE of *pgk1-alt* might play a role in stabilizing *pgk1-FL* mRNA stability, we hope that reviewers will allow that testing this model via structure-function studies would entail a tremendous amount of work that we feel lies beyond the scope of this paper. We would need to show physical binding between *Pgk1-alt* protein and *pgk1-FL* transcript, perhaps in a pull-down experiment. Then we would need to test the effects of deleting the STE or other regions of *Pgk1-alt* on mRNA binding, as well as protein stability (since many mutations in human Pgk1 greatly accelerate its proteolytic turnover), and then validate results in vivo. Although this would be an interesting and illuminating exercise, we feel it would be worthy of an entire study by itself. However, in the spirit of the question we conducted new RT-PCR and knockdown studies (Figure 3---figure supplement 2, Figure 3---figure supplement 3, Figure 3---figure supplement 4 and Figure 4---figure supplement 4) that better validate *pgk1-alt* function.

> 3\) On the other hand, the effects on hair cells and neurons is related to the expression of pkg1 in these cells? Pgk1 does not seem to be expressed in the neurogenic domain but in mature neurons. How does loss of Pgk1 affect neurogenesis at early time points?
>
> Is pgk1 expressed only in a subdomain of the SAG that could explain why only \"vestibular\" and not auditory neurons are affected? Please, show the expression of pgk1 in the entire axis of the SAG.

This question seems to suggest that *pgk1* acts cell-autonomously, but we performed a genetic mosaic experiment showing that *pgk1* acts non-autonomously (Figure 5K-R). Specifically, wild-type cells lying in the floor of the otic vesicle (within the neurogenic domain) in *pgk1-/-* mutant hosts do not properly express *etv5b* , despite their close proximity to sources of Fgf in the ear. Because *pgk1* and *Fgf* genes are coexpressed, and because blocking lactate transport phenocopies *pgk1-/-* mutants, the simplest interpretation is that Fgf and lactate are co-secreted, and both are required to act on nearby cells to fully activate the Fgf-Ras-MAPK pathway. Also as requested, Figure 4D-F' shows that *pgk1* is expressed in both anterior and posterior regions of the SAG.

> 4\) The authors indicate that other markers not related to Fgf signaling, such as Otx1b, dlx3b are not affected. However, these effects are only shown at 30hpf , when the authors mention that the effects of pgk1 are minor. At this stage, pax5 is also recovered, compared to the effect at 18hpf. Thus, to fully demonstrate that other markers in the inner ear are not changed and only Fgf signaling, the authors should show otx1b, dlx3b expression at 18hpf and Fgf ligands at these stages.

This is a good point, and we now show the earliest stages of otic expression of *fgf3* and *fgf8* in wild-type and *pgk1-/-* mutants (Figure 4---figure supplement 1). At 18 hpf, when *pax5* is first detected in the otic vesicle, *fgf3* is expressed in the hindbrain and pharyngeal endoderm but cannot be reliably detected in the ear. By 19 hpf both *fgf3* and *fgf8* expression are clearly detected in the ear and appear normal in *pgk1-/-* mutants, whereas *pax5* expression is strongly reduced in the mutant. As for regional markers, we now show that expression is normal in *pgk1-/-* mutants at 24 hpf (Figure 7). (Note, we focused on 24 hpf because several of these markers are not reliably expressed at earlier stages).

> 5\) How are neurons counted in Figure 1? Are nuclei stained with DAPI to assess individual cells? With only cytoplasmatic staining of the isl2b reporter line, can individual cells be counted? Counting information is missing in MM. Which is exactly the posterior isl2b portion? The anterior SAG is outlined in Figure 1A but not posterior SAG. Are neurons counted though confocal sections? Again, it is not clear how counting is done as Figure 1C with overexposed images nor in Figure 2GN with ISH images of highly packed neurons.

The position of the posterior SAG is now marked by red outlines in Figure 1A. We have expanded Materials and methods to include an explanation for how counts were taken (see Statistics and Quantitation). For counting *isl2b:Gfp +* cells, or cells stained by ISH, cells were counted in serial sections counter-stained with DAPI. Anti-Isl1+ cells we counted from nuclear staining in wholemount embryos.

> 6\) If pgk1 loss delays the upregulation of Fgf signaling, can the phenotype in anterior SAG or hair cells be recovered at later stages (i.e 5 dpf?).

We now present counts of hair cells and SAG neurons in wild-type embryos and *pgk1-/-* mutants at 5 dpf (Figure 5S, T). Deficiencies in both cell types are still evident at 5 dpf.

> 7\) The authors discuss that the early effects are due to strong effect on Fgf upregulation early but not later, however, it is also possible that at later stages, other mechanisms compensate the lack of pgk1alt at later stages. Could it be that pgk1alt has only a maternal effect?

We provide new data showing that *pgk1-alt* transcript is not maternally supplied (Figure 3---figure supplement 4A). Additionally, we show that *pgk1-alt* splice-blocking MO (which only targets zygotic transcript) phenocopies *sagd1* and *pgk1-/-* mutants (Figure 3---figure supplement 3 and Figure 4---figure supplement 4B).

> 8\) The loss of isl2b neurons in pgk1 mutants (Figure 5H) is almost entire and affects anterior and posterior portions of the SAG. This phenotype seems stronger than the one of sagd1 mutant. Is this so?

The reviewer is correct, both anterior and posterior portions of the SAG are deficient in *pgk1-/-* mutants, now shown in Figure 5S. The deficiencies are significant and persist through at least 5 dpf. Note that a slight deficiency of posterior SAG neurons is also seen in *sagd1* mutants, but differences were not statistically significant at any time point.

> 9\) Can the authors show lactate secretion by using a fluorescent glucose substrate?

To our knowledge, fluorescent analogs of glucose (e.g. used to track glucose transport) cannot be metabolized into fluorescent analogs of lactate. Although a FRET sensor has been developed for tracking cytosolic lactate, none are currently available for tracking extracellular lactate. We note that there have been many studies suggesting that lactate secretion and uptake are widespread in the brain, but most of these studies relied on analysis of cells in tissue culture, or used indirect methods to infer changes in extracellular lactate in vivo. A few studies used micro-dialysis to directly measure extracellular lactate in adult brain tissue, but this approach cannot be applied to small local regions in zebrafish embryos. Thus we currently lack the ability to directly visualize or specifically measure extracellular lactate and are left only with indirect evidence (e.g. inhibitors of lactate transport phenocopy the mutants).

> 10\) Authors state that Fgf ligand expression is not affected, but reduction in Fgf3 is observable in Figure 5J. Could pgk1 be upstream to Fgf signaling? On the other hand, does treatment of inner ear with SU5402 affect pgk1 expression?

The smaller domain of *fgf3* depicted in Figure 5J reflects that reduced size of sensory maculae in *pgk1-/-* mutants. New data presented in Figure 4---figure supplement 1 show that early expression of *fgf3* and *fgf8* appears normal in *pgk1-/-* mutants, and Figure 4---figure supplement 5 shows SU5402 does not alter expression of *pgk1*.

> Reviewer \#2:
>
> The paper by Kantarci et al. focuses on the phenotype of mutant in which the pgk1 gene is disrupted in zebrafish. The authors show that the mutant exhibits impaired Fgf-dependent development of hair cells and neurons in the otic vesicle and other neurons in the cranial ganglia and neural tube. The authors conclude that the crucial missing component in these mutant embryos is the loss of secreted lactate that is normally produced as a result of modified glycolysis that shunts pyruvate away from mitochondrial respiration in favor of lactate synthesis. They conclude that this secreted lactate activates the ERK MAPK pathway, which in turn primes the Fgf pathway to respond better to dynamic changes in Fgf.
>
> The work is very interesting as it demonstrates that glycolytic enzymes that are usually thought of as housekeeping enzymes, actually play crucial roles in embryonic development.
>
> In general the study is thorough, but there are several places where key experiments are missing and where more data are required.
>
> 1\) Many of the experiments require quantitation. This has been done for some, but I think it should be done for all experiments where the authors want to conclude that gene expression is altered in a quantitative way. This is the case for Figure 3, Figure 4, and Figure 5. It is also crucial for the authors to indicate how many embryos they studied for each condition and how many showed the effects they are presenting. In addition, in Figure 2M and N. These data do not seem to match with the quantitations. Why is this?

We now provide numbers of specimens studied for the images presented in each figure. Images in Figure 2M, N show *neurod* staining in the posterior SAG, which is not altered in *sagd1* mutants. It seems possible that the reviewer may have been looking at staining in other regions, so we added arrows to clarify which cells are in the SAG.

> 2\) Some of the in situs are rather poor quality and it is difficult to see the effect that the authors indicate. This is true of the in situs in Figure 3 and Figure 4S-X.
>
> In Figure 3 it is not at all evident that sprouty 4 is affected by the sagd1 mutation. Moreover, there is legend missing for Figure 3, and I think also labels missing in the Figure.
>
> In Figure 4, it is not clear what is being shown in Figure 4S-Z. These images need to be much higher quality, and more clearly labeled to be able to draw any conclusions.

We acknowledge that some of the ISH images became washed-out when they were converted to pdf, making changes in expression level more difficult to discern. In re-building the pdf of the manuscript, inserted Figures were darkened to compensate, which makes changes easier to see. We apologize for accidentally truncating Figure 3 legend -- this has been corrected. As for Figure 4S-Z, these data definitely confused the take-home message for Figure 4 and have been moved to other figures (Figure 3---figure supplement 4, Figure 3---figure supplement 5 and Figure 4---figure supplement 3). The new figures better document that additional Fgf-dependent cell types are deficient in pgk1-/- mutants (Figure 4---figure supplement 3) and show dynamic changes in transcript levels of *hs:pgk1-alt* vs. endogenous pgk1-FL following heat shock (Figure 3---figure supplement 5).

> 3\) The authors conclude that the sagd1mutations are a result of disrupting the alternative spliced form of pgk1 (pgk1-alt). This needs to be much more rigorously proven. What is the evidence in vivo that pgk1-alt, which has the exons 1a and 1b, also does not have the rest of FL pgk1 downstream of exon 6? In other words, why do they think that only this transcript (ie exons1a, 1b 2-6) then splices to exon 6a. This needs to be proven. It is important that the authors show exactly what transcripts are normally present in the embryo.

The existence of *pgk1-alt* was confirmed by cloning and sequencing the cDNA obtained by RT-PCR amplification of mRNA expressed at 24 hpf. This is now explicitly stated in the Results, and some of the supporting data are shown in Figure 3---figure supplement 2. We do not claim that exons downstream of exon 6a are missing in *pgk1- alt* transcript, only that exon 6a contains an in-frame stop codon that presumably terminates translation of downstream sequence. Please note that Figure 4A shows that *pgk1-alt* retains exons 7-10, and this is now explicitly stated in the Results (subsection "Identification of the *sagd1* locus: A novel role for Pgk1").

> They also should show that the sagd1 mutations really do lead to no protein as a result of the mutated splice site or loss of the start codon.

We lack relevant antibodies that could identify *Pgk1-alt* peptide. However, we now show data on the effects of morpholinos that were designed to mimic the lesions detected in *sagd1* mutants (Figure 3---figure supplement 3). We show that a splice blocking MO (which blocks the splice acceptor in exon 1b) prevents accumulation of *pgk1-alt* transcript (Figure 3---figure supplement 3B) and phenocopies *sagd1* (Figure 3---figure supplement 3C). Two non-overlapping translation blockers were designed to bind either of the two AUG codons (tbMO1 and tbMO2) -- these also phenocopy sagd1. Because tbMO2 binds too far downstream to block translation from the first AUG (containing the SNP found in *sagd1*), it is likely that the second AUG serves as a translation start site. Thus, the loss of splice acceptor in exon 1b is probably the relevant mutation in *sagd1*.

> Finally, they conclude that somehow the loss of pgk1-alt leads to destabilization of pgk1-FL. This needs to be demonstrated directly. It is much too speculative at the moment.

We draw no conclusions about the mechanism of *pgk1-alt* function. Rather, we only conclude that *pgk1-alt* is necessary and sufficient for accumulation of *pgk1-alt* and *pgk1-FL* mRNAs. This implies that *pgk1-alt* regulates transcription or mRNA processing or stability. Although we do speculate in the Discussion that *pgk1-alt* could work by stabilizing *pgk1-FL* transcript, we feel this is a conservative suggestion drawn from published observations. Specifically, a number of previous studies (cited in the Discussion) show that mammalian Pgk1 protein binds specific mRNAs and can alter their stability; and translation of the STE sequence in *Pgk1* is required for its own mRNA stability. In contrast there are no published accounts indicating that Pgk1 regulates transcription. As mentioned above, we hope the reviewer will agree that conducting a detailed mechanistic here study would entail an enormous amount of work that would constitute an entire paper by itself and therefore lies beyond the scope of this paper.

> 4\) The model that the authors propose replies on the concept of lactate secretion. I think that a weakness of the paper is that this is assumed to occur, but not shown. This needs to be demonstrated directly. Also, the authors should demonstrate that this really does lead to upregulation of ERK MAPK, which is a key assumption in the paper.

We agree that it would be ideal to directly demonstrate that lactate is secreted, but we know of no technology currently available that would enable us to demonstrate this. We do not assume that lactate must be secreted, nor does our summary model hinge on this issue. Instead, we suggest that lactate section is the simplest explanation for available data. Nevertheless, we added a statement in the Discussion acknowledging that we cannot exclude an alternative mechanism wherein lactate acts cell-autonomously to promote processing or secretion of Fgf ligands, although no such mechanisms have ever been reported (subsection "Enhanced glycolysis and lactate secretion promote Fgf signaling").

We have attempted to use several commercial phospho-Erk antibodies to directly observe changes in MAPK activity, but we found all of them gave such high background staining that they were not useful. However, we have now shown that the Mekinhibitor U0126 blocks the stimulatory effect of exogenous lactate (Figure 6---figure supplement 2B). This confirms that MAPK is required for the stimulatory effects of lactate in our assays.

> Reviewer \#3:
>
> Kantarci et al. present an interesting study of changes in Fgf signaling and otic placode development after alterations in glycolysis. They describe the isolation and characterization of mutations affecting expression of pgk1. One allele, sagd1, affects an alternate transcript, suggesting a mechanism that regulates levels through a post-transcriptional mechanism. The authors present evidence that changes in glycolysis alter Fgf signaling. Together it is an interesting study that would potentially have broad appeal. There are several issues that need to be addressed:
>
> The identification of the molecular nature of the sagd1 mutant is not completely clear. The authors describe the nucleotide changes as background mutations in their stocks. The causality of these changes would be strengthened by linkage analysis genotyping individual embryos.

We included the original linkage analysis from homozygosity mapping that identified *pgk1* as our top candidate for *sagd1* (Figure 3---figure supplement 1). We also show in Figures 3---figure supplement 3 and Figure 4---figure supplement 4B that MOs designed to mimic the lesions detected in *sagd1* phenocopy the mutant.

> It is not clear what the evidence is for the pgk1-alt gene model. Has this been characterized by analysis of transcripts?

We provide additional explanation of our initial cloning of *pgk1-alt* (using RT-PCR) and new RT-PCR experiments to clarify it's function (Figures 3---figure supplement 3) and expression (Figure 3---figure supplement 2).

> The authors should report whether the hs:pgk1-alt transgene is sufficient to rescue sagd1 mutants. Following the author\'s logic, the hs:pgk1-alt transgene would not rescue pgk1 mutants; this should also be tested.

We confirmed that *hs:pgk1-alt* cannot rescue *pgk1-/-* mutants (Figure 4---figure supplement 4A). Unfortunately, we were unable to test whether *hs:pgk1-alt* can rescue *sagd1* mutants because *sagd1* mutants have not been available during the last year. However, we performed an analogous experiment showing that *hs:pgk1-alt* rescues morphants injected with splice-blocking MO designed to mimic *sagd1* (Figure 4---figure supplement 4B).

> Some clarity is needed for the phenotypes of pgk1 mutants. Are they identical to sagd mutants -- grossly normal, viable until 10-12d? Are there hair cell phenotypes in pgk1 mutants? Are the trigeminal and reticulospinal phenotypes described for pgk1 mutants also found in sagd mutants? Is there compensatory pgk1 mRNA from maternal contributions?

We expanded the description of *pgk1-/-* mutants to better support the claim that they appear identical to *sagd1*. We now provide hair cell counts in Figure 5T. Figure 4 shows that *sagd1* mutants are deficient in trigeminal neurons, similar to the trigeminal deficiency seen in *pgk1-/-* mutants (now shown in Figure 4---figure supplement 3F). Figure 3---figure supplement 4 shows that *pgk1- FL* is maternally supplied, but not *pgk1-alt*. Regarding maternal function, we note that adding 2DG to *pgk1-/-* mutants does not exacerbate the phenotype, suggesting that residual maternal *pgk1* does not appreciably mitigate loss of zygotic function.

> Experiments testing the potential role of changes in plasmin in causing pgk1 mutant phenotypes were incomplete. There were no positive controls for plasminogen morpholino oligonucleotides showing that plasmin levels were actually affected. There are sensitive commercial assays available to measure plasmin activity. Plasmin levels in wt and mutant animals should be measured, and levels after MO injection should be tested.

We performed new experiments with a splice-blocking MO, which reduces accumulation of *plg* mRNA but does not rescue the SAG deficiency in *pgk1-/-* mutants (Figure 4---figure supplement 6B, C).

> The authors hypothesize that Fgf and lactate converge on Mapk signaling. They should test this directly by assessing whether lactate treatment can partially rescue SAG neuron number after Mapk inhibitor treatment.

This is a terrific idea. New data in Figure 6---figure supplement 2 show that the Mek inhibitor U0126 blocks the ability of lactate to stimulate SAG production. This is consistent with the idea that lactate acts though Raf kinase, upstream of Mek, and provides strong support for the hypothesis that lactate, like Fgf, feeds through the MAPK pathway.

> The authors should comment on whether the interference with lactate metabolism on Fgf signaling is specific, or whether other signaling pathways are also affected.

We cannot exclude involvement of other pathways, but the ability of U0126 to mimic *pgk1-/-* mutants and to block the effects of lactate suggest that a deficiency of MAPK is sufficient to explain the phenotype.
